Market Spotlight: Glioblastoma (GBM)
Market Spotlight: Glioblastoma (GBM)
$1,318.00
This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 77,000 incident cases of glioblastoma worldwide, and forecasts that number to increase to 91,800 incident cases by 2028.
- It is estimated that the majority of diagnosed cases were in males in 2019. Approved drugs in the glioblastoma space focus on DNA, vascular endothelial growth factor, DNA synthesis, protein synthesis, RNA synthesis, the immune system, and oncolytic virus therapy. These drugs are administered via the intravenous, intratumoral, and oral routes for glioblastoma.
- The majority of industry-sponsored drugs in active clinical development for glioblastoma are in Phase II, with only one drug in the NDA/BLA phase.
- Therapies in mid- and late-stage development for glioblastoma focus on a wide variety of targets. The majority of pipeline drugs for glioblastoma are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the glioblastoma space comprise topline Phase I/II trial results for EO2401 and Calquence, topline Phase II trial results for Fyarro, lisavanbulin, and Berubicin, topline Phase III trial results for eflornithine, Phase III updated trial results for DCVax-Brain, and an expected CHMP opinion and European approval decision for omburtamab, as well as an estimated PDUFA date for biosimilar bevacizumab (Mylan/Biocon).
- The overall likelihood of approval of a Phase I solid tumors asset is 5.3%, and the average probability a drug advances from Phase III is 42.3%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for glioblastoma have been in the early and mid-phases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.
- The US has a substantial lead in the number of glioblastoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the glioblastoma space is dominated by completed trials. Merck & Co has the highest number of completed clinical trials for glioblastoma, with 82 trials.
- Merck & Co leads industry sponsors with the highest overall number of clinical trials for glioblastoma, closely followed by Roche.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Patient segmentation
8 Symptoms
8 Risk factors
9 Diagnosis
10 TREATMENT
10 Surgery
10 Radiation therapy
10 Chemotherapy
10 Tumor-treating fields (TTFs)
11 Targeted therapy
12 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
37 RECENT EVENTS AND ANALYST OPINION
37 DNX-2401 for Glioblastoma (November 20, 2020)
38 Omburtamab for Glioblastoma (October 16, 2020)
40 AG-881 for Glioblastoma (May 29, 2020)
41 FT-2102 for Glioblastoma (May 28, 2020)
43 KEY UPCOMING EVENTS
44 KEY REGULATORY EVENTS
44 Pioneering Japan Approval For Daiichi’s Oncolytic Virus In Glioma
44 Innovent’s Adalimumab And Bevacizumab Get New Indications In China
45 PROBABILITY OF SUCCESS
46 LICENSING AND ASSET ACQUISITION DEALS
46 Kazia Therapeutics Enters Collaboration With Cornell University
46 Yale Unveils Research Pact With D&D Pharmatech
46 Lineage, Immunomic Partner On Brain Cancer Immunotherapy
46 UroGen, Johns Hopkins Investigate Brain Cancer Immunotherapy
47 Simcere Picks Up Kazia’s Paxalisib In China-Plus Area
47 Chimerix Pays $78m To Acquire Oncoceutics
47 Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases
48 Connectyx Explores Use Of NCI Antibody For Brain Cancer
48 Telix Chooses China Grand In Greater China Alliance
48 City of Hope Licenses CTLX-CAR-T Candidate To Chimeric
48 Cytovia Obtains Rights To CytoImmune’s CAR Candidate
50 REVENUE OPPORTUNITY
51 CLINICAL TRIAL LANDSCAPE
52 Sponsors by status
53 Sponsors by phase
54 Recent Events
55 BIBLIOGRAPHY
57 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of glioblastoma, 2019–28
19 Figure 2: Overview of pipeline drugs for glioblastoma in the US
19 Figure 3: Pipeline drugs for glioblastoma, by company
20 Figure 4: Pipeline drugs for glioblastoma, by drug type
20 Figure 5: Pipeline drugs for glioblastoma, by classification
38 Figure 6: DNX-2401 for Glioblastoma (November 20, 2020): Phase II – CAPTIVE/KEYNOTE-192 – w/Keytruda
40 Figure 7: Omburtamab for Glioblastoma (October 16, 2020): Phase II/III – 101 (Neuroblastoma Central Nervous System/Leptomeningeal Metastases)
42 Figure 8: FT-2102 for Glioblastoma (May 28, 2020): Phase I/II – 2101-ONC-102
43 Figure 9: Key upcoming events in glioblastoma
45 Figure 10: Probability of success in the solid tumors pipeline
51 Figure 11: Clinical trials in glioblastoma
51 Figure 12: Top 10 drugs for clinical trials in glioblastoma
52 Figure 13: Top 10 companies for clinical trials in glioblastoma
52 Figure 14: Trial locations in glioblastoma
53 Figure 15: Glioblastoma trials status
54 Figure 16: Glioblastoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Global incident cases of glioblastoma, 2019–28
15 Table 2: Incident cases of glioblastoma, by gender, 2019
17 Table 3: Marketed drugs for glioblastoma
21 Table 4: Pipeline drugs for glioblastoma in the US
37 Table 5: DNX-2401 for Glioblastoma (November 20, 2020)
39 Table 6: Omburtamab for Glioblastoma (October 16, 2020)
40 Table 7: AG-881 for Glioblastoma (May 29, 2020)
41 Table 8: FT-2102 for Glioblastoma (May 28, 2020)
50 Table 9: Historical global sales, by drug ($m), 2016–20
50 Table 10: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #1 
Sign up to the